Endocrine Pharmacology USMLE Step 1 Practice Question
A 29-year-old woman with a 12-year history of type 1 diabetes mellitus presents to her endocrinologist for a follow-up visit regarding persistent postprandial glucose excursions, with peak readings consistently around 280 mg/dL occurring approximately 1–2 hours after meals despite adherence to her current mealtime insulin regimen. Her HbA1c is 8.2%, fasting glucose averages 110 mg/dL, and her C-peptide level is undetectable, confirming absent endogenous insulin secretion. Vital signs are stable: blood pressure 118/74 mmHg, heart rate 76 bpm, BMI 23 kg/m². Physical examination is unremarkable. She denies nausea, vomiting, or other gastrointestinal symptoms. Her endocrinologist decides to add a subcutaneous adjunctive medication that works by decreasing postprandial glucagon secretion and delaying gastric emptying. Which of the following drugs was most likely added?
Answer choices
- APramlintideCorrect answer
- BSitagliptin
- CSemaglutide
- DMetformin
- ERepaglinide
- FAcarbose
See the full explanation
Get the correct-answer rationale, why each distractor is wrong, the underlying mechanism, and high-yield associations — plus adaptive practice that targets your weak areas — with a free MedBoardPRO account.